Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2010  |  Volume : 6  |  Issue : 1  |  Page : 58--64

High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on dosimetry aspects and acute toxicity in the Indian scenario


Sandeep De, Venkatesan Kannan, Sudesh Deshpande, Vivek Anand, Yogesh Ghadi 
 Department of Radiation Oncology, P. D. Hinduja National Hospital and Medical Research Center, Veer Savarkar Road, Mahim, Mumbai, Maharashtra, India

Correspondence Address:
Venkatesan Kannan
Department of Radiation Oncology, P.D.Hinduja National Hospital & Medical Research Center, V. S. Road, Mahim, Mumbai-400016, Maharashtra
India

Background and Purpose: Dose escalation improves local control in prostate cancer. In this study we assess the feasibility of dose escalation to prostate and / or seminal vesicles to 76 Gy with intensity-modulated radiotherapy (IMRT); report data on dosimetry and acute toxicity in 40 patients at P. D. Hinduja National Hospital and Medical Research Center, Mumbai. Materials and Methods: In the period from May 2006 to September 2008, 40 consecutive patients with localized prostate adenocarcinoma (T1- 3 N0) were definitively treated with IMRT to a dose of 76 Gy / 38 fractions. Patients were seen on a weekly basis during treatment, and one month (M1) and three months (M3) thereafter. The radiation therapy oncology group (RTOG) toxicity scale was used to evaluate acute gastrointestinal (GI) and genitourinary (GU) toxicities. Additional symptoms such as rectal blood loss, urgency, dysuria, urinary frequency, nocturia, incontinence were scored as well. Results: All 40 patients completed treatment successfully. Acute RTOG Grade 1 and Grade 2 GI toxicities were noted in 47.5% (19 patients) and 12.5% (five patients) respectively, leaving 40% (16 patients) free of any acute toxicity. Thirty-six (90%) and four patients (10%) had Grade 0-1 and Grade 2 acute RTOG-scaled GU toxicity respectively. There was no Grade 3 or higher GI / GU toxicity. Conclusions: The escalated dose of 76 Gy to the prostate with IMRT was very well tolerated by all our patients with acceptable acute GU and GI toxicity, thereby, establishing the feasibility of dose escalation in the Indian scenario.


How to cite this article:
De S, Kannan V, Deshpande S, Anand V, Ghadi Y. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on dosimetry aspects and acute toxicity in the Indian scenario.J Can Res Ther 2010;6:58-64


How to cite this URL:
De S, Kannan V, Deshpande S, Anand V, Ghadi Y. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on dosimetry aspects and acute toxicity in the Indian scenario. J Can Res Ther [serial online] 2010 [cited 2019 Oct 13 ];6:58-64
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2010;volume=6;issue=1;spage=58;epage=64;aulast=De;type=0